文献速递骨质疏松与钙磷/甲状旁腺

女性对骨质疏松症治疗的价值观与偏好:系统综述

Women's Values and Preferences Regarding Osteoporosis Treatments: A Systematic Review.
PubMed 文献 · J Clin Endocrinol Metab · 2019-01-01

该系统综述纳入26项研究、共15,348名女性(平均年龄66岁),总结其骨质疏松药物治疗的价值观与偏好。女性同等重视疗效与不良事件,其次为用药便利性与对日常作息的影响,偏好低频给药、口服途径,若注射剂给药频率更低则偏好注射而非口服。治疗费用与疗程对决策影响较小,对乳腺癌和恢复子宫出血的恐惧是不选择雌激素治疗的常见原因,钙和维生素D被视为安全自然。

要点

  • 女性同等重视骨质疏松药物的疗效与不良事件。
  • 偏好低频给药和口服途径,低频注射也可接受。
  • 费用与疗程对治疗决策影响较小。

核心结论

  • 开始骨质疏松药物治疗的女性同等重视疗效与副作用,并偏好低频给药的药物。
  • 若注射药物给药频率较低,女性认为其可接受。
  • 需要更多关于患者价值观与偏好的研究来指导骨质疏松决策。

研究设计与样本

  • 系统综述,全面检索多个数据库,纳入已开始或即将开始任何骨质疏松药物治疗的女性研究,不限语言。
  • 由两名评价者独立筛选研究和提取数据,结果进行叙述性综合。
  • 共纳入26项研究,报告15,348名女性,平均年龄66岁。

主要发现

  • 女性同等考虑疗效和不良事件,其次是服药便利性及其对日常作息的影响。
  • 偏好低频给药、口服途径;若注射剂给药频率更低,则偏好注射而非口服。
  • 治疗费用和疗程是决策中较不重要的因素。
  • 对乳腺癌和恢复子宫出血的恐惧是不选择雌激素治疗的常见原因。
  • 钙和维生素D被视为安全且自然;偏好不受年龄、既往药物暴露或就业状态影响。

临床怎么用

  • 与女性患者讨论骨质疏松治疗时,应同等沟通疗效与不良事件,并考虑其给药频率和途径偏好。
  • 可告知低频注射方案是可接受的选项,费用和疗程的重要性相对较低。
  • 对考虑雌激素治疗者,需关注其对乳腺癌和子宫出血的恐惧。

局限性

  • 结果为叙述性综合,未提供定量合并估计。
  • 需要更多关于患者价值观与偏好的研究来指导骨质疏松决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Several treatments are available to reduce the risk of fragility fractures associated with osteoporosis. The choice of treatment requires knowledge of patients' values and preferences. The aim of the present study was to summarize what is known about the values and preferences relevant to the management of osteoporosis in women. METHODS: We conducted a comprehensive search of several databases for studies reported in any language that had included women who had already started or were about to start any pharmacological therapy for osteoporosis. Pairs of reviewers independently selected the studies and extracted the data. The results were synthesized narratively. RESULTS: We included 26 studies reporting on 15,348 women (mean age, 66 years). The women considered the effectiveness and adverse events equally, followed by the convenience of taking the drug and its effect on daily routine (less frequent dosing was preferred, the oral route was preferred, and the injectable route was preferred over oral if given less frequently). The treatment cost and duration were less important factors for decision making. Fear of breast cancer and fear of resuming uterine bleeding were common reasons for not choosing estrogen therapy. Calcium and vitamin D were viewed as safe and natural. Across the studies, the preferences were not affected by age, previous drug exposure, or employment status. CONCLUSIONS: Women starting osteoporosis medications value effectiveness and side effects equally and prefer medications given less frequently. Injectable drugs appear acceptable if given less frequently. More research on patient values and preferences is needed to guide decision making in osteoporosis.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Barrionuevo P, Gionfriddo MR, Castaneda-Guarderas A, et al. Women's Values and Preferences Regarding Osteoporosis Treatments: A Systematic Review. J Clin Endocrinol Metab. 2019. PMID: 30907968. doi:10.1210/jc.2019-00193

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。